Tirabrutinib Inhibitor

Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2nM).

Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep, 2014 Mar, 9(1):44-9.
Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep, 2014 Mar, 9(1):44-9.
Harriet S. Walter et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016 Jan 28, 127(4): 411-419.
Harriet S. Walter et al. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood, 2016 Jan 28, 127(4): 411-419.

Small volumes of Tirabrutinib, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5764488 is an inhibitor targeting Tirabrutinib.